Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB001158 + daratumumab in relapsed/refractory multiple myeloma
NCT03837509Phase 2Terminated
- Sponsor
- Incyte
- Start
- Sep 2019
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of numidargistat in multiple myeloma (MM) (3 arms), sponsored by Incyte. Primary endpoints: Treatment-emergent Adverse Event at 454 days and Overall Response Rate at 386 days. Started Sep 2019; status: terminated.
02
Drugs
numidargistat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03837509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03837509.